Merck's Sotatercept Therapy for Lung Disease Gains UK Approval - PRESS AI WORLD
PRESSAI
Recent Posts
side-post-image
side-post-image
Economy

Merck's Sotatercept Therapy for Lung Disease Gains UK Approval

share-iconWednesday, January 01 comment-icon3 weeks ago 7 views
News sources:
reutersREUTERS
Merck's Sotatercept Therapy for Lung Disease Gains UK Approval

Credited from: REUTERS

  • The UK’s **Medicines and Healthcare products Regulatory Agency (MHRA)** has approved Merck’s therapy for a **rare lung condition**.
  • The drug, **sotatercept**, was previously approved in the **U.S.** and the **European Union**, expanding its availability.
  • Approval is based on a study showing **improved exercise capacity** in patients with **pulmonary arterial hypertension**.
  • Merck acquired sotatercept in its **$11.5 billion** deal with **Acceleron Pharma** in 2021 to strengthen its cardiovascular portfolio.
  • **Winrevair**, the brand name for sotatercept, is priced at **$14,000 per vial** in the U.S. and projected sales may reach **$1 billion** by 2025.

For more information, visit the original article here.


Gallery

SHARE THIS ARTICLE:

nav-post-picture
nav-post-picture